Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Herceptin, Enbrel Face First Biosimilar Rivals In Japan But Outlook Uncertain

Executive Summary

The first biosimilar versions in Japan of two major biologic therapies, Herceptin and Enbrel, have been awarded reimbursement prices, clearing the way for launch, but commercial prospects remain uncertain.

You may also be interested in...

Deal Watch Asia Focus: Merck Partners With Alibaba For Entry To Digital Health In China

China’s Everest licenses global rights to Novartis FGFR4 inhibitor, while Altogen and Lynkogen partner in NASH and metabolic disease.

Oncology, Multinationals Dominate Japan 2017 Approvals

It was another busy year for Japanese regulators, who approved 38 new drugs in the fiscal year up to the end of this March, roughly maintaining the pace of the the previous 12 months and bringing some important new therapies to patients. New products for oncology and biologics featured heavily, with foreign multinationals dominating the list.

Interview: New Chugai CEO Lays Course As He Takes Reins (Part 2).

Chugai's new CEO Tatsuro Kosaka took up his position in March and is charged with taking the major Japanese company through the next stage of development as key new products reach the global market and others begin to face generic competition. In this second and final part of an exclusive interview with Scrip, he talks about major mid-term growth prospects, recent pricing reforms in Japan, and how Chugai is tapping into novel disruptive technologies. 


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts